|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
1990
|
|
gptkbp:approvedBy
|
gptkb:Germany
|
|
gptkbp:ATCCode
|
N03AF02
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
extended-release tablet
|
|
gptkbp:brand
|
gptkb:Trileptal
Oxtellar XR
|
|
gptkbp:CASNumber
|
28721-07-5
|
|
gptkbp:cause
|
gptkb:SIADH
|
|
gptkbp:contraindication
|
hypersensitivity to oxcarbazepine
|
|
gptkbp:developedBy
|
gptkb:carbamazepine
|
|
gptkbp:eliminationHalfLife
|
1-5 hours
active metabolite: 9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
C15H12N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oxcarbazepine
|
|
gptkbp:lactationRisk
|
excreted in breast milk
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
voltage-gated sodium channel blocker
|
|
gptkbp:meltingPoint
|
215-216°C
|
|
gptkbp:metabolism
|
liver
licarbazepine
|
|
gptkbp:molecularWeight
|
252.27 g/mol
|
|
gptkbp:notRecommendedFor
|
absence seizures
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
may cause birth defects
|
|
gptkbp:proteinBinding
|
40%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1082
4614
4454
|
|
gptkbp:riskOfDrugInteraction
|
yes
|
|
gptkbp:riskOfStevensJohnsonSyndrome
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
rash
drowsiness
hyponatremia
|
|
gptkbp:UNII
|
V2V3JFMCDF
|
|
gptkbp:usedFor
|
epilepsy
partial seizures
generalized tonic-clonic seizures
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:trigeminal_neuralgia
gptkb:Trileptal
|
|
gptkbp:bfsLayer
|
6
|